After big buyout, team looks to lead hepatitis B, NASH drug maker to $100M IPO
Two-year-old Aligos Therapeutics Inc. is seeking a $100 million initial public offering to help take its experimental chronic hepatitis B drugs into clinical trials.
The South San Francisco company is the work of much of the executive team that translated $74 million in investments for hepatitis C-focused Alios BioPharma Inc. of South San Francisco into a $1.75 billion cash deal in 2014 with Johnson& Johnson's (NYSE: JNJ) Janssen Pharmaceutical unit.
Janssen ultimately dumped Alios' oral drug,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Clinical Trials | Health Management | Hepatitis | Hepatitis B | Hepatitis C